Skip to main content

Table 1 Inclusion and exclusion criteria

From: Access to systemic anti-cancer therapies for women with secondary breast cancer—protocol for a mixed methods systematic review

  Study inclusion criteria Study exclusion criteria
Population: Studies which report women aged > 18 and with a confirmed SBC diagnosis who accessed/received treatment with SACT. This will include studies which report all clinical sub types across all sites of metastases and will include de novo presentations Studies which report primary and/or locally advanced (LABC) early stage (I-III) breast cancer only
Studies which report (comparative) treatment effect and efficacy
Males with a secondary breast cancer diagnosis as this is classified as a rare disease
Phenomena of interest: Studies which explore individual, clinical and contextual factors associated with access to SACT for SBC Studies which do not explore individual, clinical and contextual factors associated with the primary outcome
Intervention/Exposure: Studies reporting individual factors, which include, age, gender, sexual orientation, race/ethnicity, socioeconomic status, education, language and literacy, psychosocial characteristics
Clinical characteristics which include, sub type, HR status, HER2 status, previous treatment response, physician characteristics
Contextual factors which include geography and geographical location, distance, travel time, health region, catchment/referral areas and organisational factors including, health care system factors, capacity, service availability
Studies which do not report individual, clinical and contextual factors associated with the primary outcome
Outcome(s): Studies which report access in terms of receipt non receipt of one or more a systemic anti-cancer therapy(ies)
For the purposes of the review access will be defined as receipt/non receipt of a systemic anti-cancer therapy which will include chemotherapy, immunotherapy, targeted therapy and hormone/endocrine therapy
Studies which do not report the primary outcome measure of receipt/non receipt of one or more a systemic anti-cancer therapy(ies)
Types of study: Quantitative, qualitative and mixed methods studies. This will include observational, cross sectional, longitudinal and analytic studies, including, epidemiological studies, case control and cohort studies
Qualitative studies will include designs such as phenomenology, grounded theory, ethnography, action research and feminist research
Mixed method studies will only be considered if data from the quantitative or qualitative components can be clearly extracted
Peer reviewed, original research studies published in English language from January 2000 onwards reporting quantitative, qualitative or mixed methods
Studies which report (comparative) treatment effect, efficacy and studies reporting clinical trials of systemic anti-cancer therapies, as whilst RCT is not a specific exclusion criteria it is likely that RCTs will measure treatment effect as opposed to access as an outcome and would therefore be excluded